Glubio Pharmaceutical

Glubio Therapeutics is a clinical-stage biotechnology company focused on the development of targeted protein degradation (TPD) therapies. The company utilizes its proprietary GLU-MOD and GLU-PRO platforms to design and optimize molecular glues and PROTACs for high-value targets in oncology and autoimmune diseases. Its lead program, GLU-001, is a potent GSPT1 degrader currently undergoing Phase 1 clinical evaluation for patients with relapsed or refractory acute myeloid leukemia. Glubio maintains a global presence with research and development centers in Shenzhen, Shanghai, and San Diego. The company has successfully raised significant venture capital from leading investors such as Lilly Asia Ventures and Qiming Venture Partners to advance its diverse pipeline of protein degraders. By targeting "undruggable" proteins, Glubio aims to provide transformative treatment options for patients with limited therapeutic alternatives.